Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Metastatic Appendiceal Carcinoma
NCT03287947Phase 2Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2017
- Primary completion
- Sep 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in Appendiceal carcinoma, sponsored by Wake Forest University Health Sciences. Started Nov 2017; status: terminated.
02
Drugs
nintedanib
03
Conditions
Appendiceal carcinoma
Beyond the preview
Go deeper on NCT03287947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287947.